Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation.
Transplant Rev (Orlando)
; 38(3): 100857, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38749097
ABSTRACT
Hereditary forms of hemolytic uremic syndrome (HUS), formerly known as atypical HUS, typically involve mutations in genes encoding for components of the alternative pathway of complement, therefore they are often referred to as complement-mediated HUS (cHUS). This condition has a high risk of recurrence in the transplanted kidney, leading to accelerated graft loss. The availability of anti-complement component C5 antibody eculizumab has enabled successful transplantation with a notably reduced recurrence rate and improved prognosis. Open questions are related to the potential for complement inhibitor discontinuation, ideal timing of treatment withdrawal, and patient selection based on genetic abnormalities. Our review delves into the pathophysiology, classification, genetic predispositions, and management strategies for cHUS in the native and transplant kidneys.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Recurrence
/
Kidney Transplantation
/
Antibodies, Monoclonal, Humanized
/
Hemolytic-Uremic Syndrome
Limits:
Humans
Language:
En
Journal:
Transplant Rev (Orlando)
Journal subject:
TRANSPLANTE
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United States